TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Brief Summary: To determine if AMG 386 plus pegylated liposomal doxorubicin (PLD) is superior to placebo plus PLD as measured by progression-free survival (PFS)

The hypothesis for this study is that AMG 386 plus PLD will prolong PFS compared to placebo plus PLD in women with recurrent partially platinum sensitive or resistant epithelial ovarian, primary peritoneal or fallopian tube cancer.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Liposomal Doxorubicin | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Intervention Type: DRUG; Name: AZD2281; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Liposomal Doxorubicin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: AZD2281; Assigned to Arm(s): 1
B: Arm Label: Mirvetuximab Soravtansine; Type: EXPERIMENTAL; Interventions: Drug: Mirvetuximab soravtansine | Arm Label: Investigator's Choice (IC) Chemotherapy; Type: EXPERIMENTAL; Interventions: Drug: Paclitaxel, Drug: Pegylated liposomal doxorubicin, Drug: Topotecan | Intervention Type: DRUG; Name: Mirvetuximab soravtansine; Assigned to Arm(s): Mirvetuximab Soravtansine | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Investigator's Choice (IC) Chemotherapy | Intervention Type: DRUG; Name: Pegylated liposomal doxorubicin; Assigned to Arm(s): Investigator's Choice (IC) Chemotherapy | Intervention Type: DRUG; Name: Topotecan; Assigned to Arm(s): Investigator's Choice (IC) Chemotherapy
C: Arm Label: Pazopanib/Paclitaxel association; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib, Drug: Paclitaxel | Arm Label: Paclitaxel alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): Pazopanib/Paclitaxel association | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Paclitaxel alone, Pazopanib/Paclitaxel association
D: Arm Label: Placebo plus PLD; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo plus PLD | Arm Label: AMG386 plus PLD; Type: EXPERIMENTAL; Interventions: Drug: AMG386 plus PLD | Intervention Type: DRUG; Name: AMG386 plus PLD; Assigned to Arm(s): AMG386 plus PLD | Intervention Type: DRUG; Name: Placebo plus PLD; Assigned to Arm(s): Placebo plus PLD

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Brief Summary: To determine if AMG 386 plus pegylated liposomal doxorubicin (PLD) is superior to placebo plus PLD as measured by progression-free survival (PFS)

The hypothesis for this study is that AMG 386 plus PLD will prolong PFS compared to placebo plus PLD in women with recurrent partially platinum sensitive or resistant epithelial ovarian, primary peritoneal or fallopian tube cancer.


Options:
A: Arm Label: Telcyta + Liposomal Doxorubicin; Type: EXPERIMENTAL; Interventions: Drug: Telcyta, Drug: Liposomal Doxorubicin | Arm Label: Liposomal Doxorubicin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Liposomal Doxorubicin | Intervention Type: DRUG; Name: Telcyta; Assigned to Arm(s): Telcyta + Liposomal Doxorubicin | Intervention Type: DRUG; Name: Liposomal Doxorubicin; Assigned to Arm(s): Liposomal Doxorubicin, Telcyta + Liposomal Doxorubicin
B: Arm Label: paclitaxel and pazopanib; Type: EXPERIMENTAL; Interventions: Drug: paclitaxel, Drug: pazopanib | Arm Label: paclitaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: paclitaxel | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): paclitaxel, paclitaxel and pazopanib | Intervention Type: DRUG; Name: pazopanib; Assigned to Arm(s): paclitaxel and pazopanib
C: Arm Label: Placebo plus PLD; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo plus PLD | Arm Label: AMG386 plus PLD; Type: EXPERIMENTAL; Interventions: Drug: AMG386 plus PLD | Intervention Type: DRUG; Name: AMG386 plus PLD; Assigned to Arm(s): AMG386 plus PLD | Intervention Type: DRUG; Name: Placebo plus PLD; Assigned to Arm(s): Placebo plus PLD
D: Intervention Type: DRUG; Name: pegylated liposomal Doxorubicin (CAELYX) & Carboplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Paclitaxel & Carboplatin; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Brief Summary: To determine if AMG 386 plus pegylated liposomal doxorubicin (PLD) is superior to placebo plus PLD as measured by progression-free survival (PFS)

The hypothesis for this study is that AMG 386 plus PLD will prolong PFS compared to placebo plus PLD in women with recurrent partially platinum sensitive or resistant epithelial ovarian, primary peritoneal or fallopian tube cancer.


Options:
A: Arm Label: Olaparib and Cediranib; Type: EXPERIMENTAL; Interventions: Drug: Olaparib, Drug: Cediranib | Arm Label: Olaparib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olaparib | Intervention Type: DRUG; Name: Olaparib; Assigned to Arm(s): Olaparib, Olaparib and Cediranib | Intervention Type: DRUG; Name: Cediranib; Assigned to Arm(s): Olaparib and Cediranib
B: Arm Label: Placebo plus PLD; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo plus PLD | Arm Label: AMG386 plus PLD; Type: EXPERIMENTAL; Interventions: Drug: AMG386 plus PLD | Intervention Type: DRUG; Name: AMG386 plus PLD; Assigned to Arm(s): AMG386 plus PLD | Intervention Type: DRUG; Name: Placebo plus PLD; Assigned to Arm(s): Placebo plus PLD
C: Arm Label: Arm I; Type: EXPERIMENTAL; Interventions: Drug: docetaxel, Drug: vandetanib | Arm Label: Arm II; Type: EXPERIMENTAL; Interventions: Drug: docetaxel, Drug: vandetanib | Intervention Type: DRUG; Name: docetaxel; Assigned to Arm(s): Arm I, Arm II | Intervention Type: DRUG; Name: vandetanib; Assigned to Arm(s): Arm I, Arm II
D: Arm Label: Rucaparib; Type: EXPERIMENTAL; Interventions: Drug: Rucaparib | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rucaparib; Assigned to Arm(s): Rucaparib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety and Tolerability of TMC435 vs Placebo as Part of a Treatment Regimen Including Peginterferon α-2a and Ribavirin in Hepatitis C, Genotype 1 Infected Subjects Who Relapsed After Previous Interferon-based Therapy
Brief Summary: The purpose of this study is to investigate the effectiveness and safety of TMC435 compared with placebo in patients who are infected with genotype 1 hepatitis C virus who relapsed after previous interferon-based therapy. Patients will also receive peginterferon alfa-2a and ribavirin as part of their treatment.


Options:
A: Arm Label: Standard; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pegylated Interferon alfa-2b, Drug: Ribavirin, Drug: Sofosbuvir | Arm Label: Simeprevir + Sofosbuvir; Type: EXPERIMENTAL; Interventions: Drug: Simeprevir, Drug: Sofosbuvir | Intervention Type: DRUG; Name: Pegylated Interferon alfa-2b; Assigned to Arm(s): Standard | Intervention Type: DRUG; Name: Simeprevir; Assigned to Arm(s): Simeprevir + Sofosbuvir | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): Standard | Intervention Type: DRUG; Name: Sofosbuvir; Assigned to Arm(s): Simeprevir + Sofosbuvir, Standard
B: Arm Label: Arm 1 (Control Arm); Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo, Biological: Peginterferon alfa-2a, Drug: Ribavirin | Arm Label: Arm 2 (Boceprevir Arm); Type: EXPERIMENTAL; Interventions: Drug: Boceprevir, Biological: Peginterferon alfa-2a, Drug: Ribavirin | Intervention Type: DRUG; Name: Boceprevir; Assigned to Arm(s): Arm 2 (Boceprevir Arm) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Arm 1 (Control Arm) | Intervention Type: BIOLOGICAL; Name: Peginterferon alfa-2a; Assigned to Arm(s): Arm 1 (Control Arm), Arm 2 (Boceprevir Arm) | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): Arm 1 (Control Arm), Arm 2 (Boceprevir Arm)
C: Arm Label: SOF/VEL 12 Weeks; Type: EXPERIMENTAL; Interventions: Drug: SOF/VEL | Arm Label: SOF+RBV 24 Weeks; Type: EXPERIMENTAL; Interventions: Drug: SOF, Drug: RBV | Intervention Type: DRUG; Name: SOF/VEL; Assigned to Arm(s): SOF/VEL 12 Weeks | Intervention Type: DRUG; Name: SOF; Assigned to Arm(s): SOF+RBV 24 Weeks | Intervention Type: DRUG; Name: RBV; Assigned to Arm(s): SOF+RBV 24 Weeks
D: Arm Label: TMC435; Type: EXPERIMENTAL; Interventions: Drug: TMC435, Drug: Peginterferon alpha-2a (PegIFN alpha-2a), Drug: Ribavirin (RBV) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Peginterferon alpha-2a (PegIFN alpha-2a), Drug: Ribavirin (RBV) | Intervention Type: DRUG; Name: TMC435; Assigned to Arm(s): TMC435 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Peginterferon alpha-2a (PegIFN alpha-2a); Assigned to Arm(s): Placebo, TMC435 | Intervention Type: DRUG; Name: Ribavirin (RBV); Assigned to Arm(s): Placebo, TMC435

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Multi-center Trial of Mycophenolate Mofetil for the Patient With High Risk Membranous Nephropathy
Brief Summary: Cyclosporin decreases proteinuria and improve renal function in patients with idiopathic membranous nephropathy, but has a risk of side effects such as nephrotoxicity. The investigators plan to the study to evaluate whether mycophenolate mofetil (MMF) could be a reasonable alternative with fewer side effect.


Options:
A: Arm Label: late intervention; Type: OTHER; Interventions: Drug: Cyclophosphamide and steroids | Arm Label: early intervention; Type: EXPERIMENTAL; Interventions: Drug: Cyclophosphamide and steroids | Intervention Type: DRUG; Name: Cyclophosphamide and steroids; Assigned to Arm(s): early intervention, late intervention
B: Arm Label: Mycophenolate mofetil, low dose steroid; Type: EXPERIMENTAL; Interventions: Drug: Mycophenolate mofetil, low dose steroid | Arm Label: Cyclosporin, low dose steroid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cyclosporin, low dose steroid | Intervention Type: DRUG; Name: Mycophenolate mofetil, low dose steroid; Assigned to Arm(s): Mycophenolate mofetil, low dose steroid | Intervention Type: DRUG; Name: Cyclosporin, low dose steroid; Assigned to Arm(s): Cyclosporin, low dose steroid
C: Arm Label: RITUXIMAB; Type: EXPERIMENTAL; Interventions: Drug: Rituximab | Arm Label: Corticosteroids and Cyclophosphamide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylprednisolone, Drug: Cyclophosphamide | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): RITUXIMAB | Intervention Type: DRUG; Name: Methylprednisolone; Assigned to Arm(s): Corticosteroids and Cyclophosphamide | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Corticosteroids and Cyclophosphamide
D: Arm Label: Rituximab Treatment Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rituximab | Arm Label: Cyclosporine Treatment Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cyclosporine | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Rituximab Treatment Arm | Intervention Type: DRUG; Name: Cyclosporine; Assigned to Arm(s): Cyclosporine Treatment Arm

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Financial Incentives for Home-based Health Management: A Pilot Randomized Trial
Brief Summary: The primary objective of the study is to assess the effect of financial incentives on the use of home health monitoring devices among high-risk patients. In addition, there are three secondary objectives: (1) obtain preliminary evidence regarding whether the monetary value of incentives has a differential effect on the use of home health monitoring devices; (2) identify potential barriers that prohibit regular use of home-based health devices using qualitative data; and (3) assess the usability of a newly developed web portal and its feasibility for future randomized clinical trials aimed at changing health-related behaviors.


Options:
A: Arm Label: Geriatric Diabetes Team Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral | Arm Label: Atention Control Arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Behavioral; Assigned to Arm(s): Geriatric Diabetes Team Intervention
B: Arm Label: Advanced care; Type: OTHER; Interventions: Other: Advanced Care | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Advanced Care; Assigned to Arm(s): Advanced care
C: Arm Label: Electronic disease management decision support; Type: OTHER; Interventions: Other: Electronic disease management decision support | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Electronic disease management decision support; Assigned to Arm(s): Electronic disease management decision support
D: Arm Label: Active Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Financial Incentive Group I; Type: EXPERIMENTAL; Interventions: Behavioral: Financial Incentive Group I | Arm Label: Financial Incentives Group II; Type: EXPERIMENTAL; Interventions: Behavioral: Financial Incentive Group II | Intervention Type: BEHAVIORAL; Name: Financial Incentive Group I; Assigned to Arm(s): Financial Incentive Group I | Intervention Type: BEHAVIORAL; Name: Financial Incentive Group II; Assigned to Arm(s): Financial Incentives Group II

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intraoperative Lung Protective Ventilation in Abdominal Surgery: A Randomized Controlled Study
Brief Summary: The purpose of this study is to compare the influence of a lung protective ventilation with conventional ventilation on postoperative complications following major abdominal surgery.


Options:
A: Intervention Type: OTHER; Name: Abdominal surgery; Assigned to Arm(s): N/A
B: Intervention Type: OTHER; Name: Mild intraoperative hypercapnia (50 mmHg vs. 30 mmHg); Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: Supplemental oxygen (80% vs. 30%); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A
C: Arm Label: Individualized ventilation; Type: EXPERIMENTAL; Interventions: Procedure: Alveolar recruitment maneuver, Procedure: Calculation of optimal PEEP | Arm Label: Individualized vent. + postop. CPAP; Type: EXPERIMENTAL; Interventions: Procedure: Alveolar recruitment maneuver, Procedure: Calculation of optimal PEEP, Procedure: Postoperative CPAP | Arm Label: Standard ventilation; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Standard vent. + postoperative CPAP; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Postoperative CPAP | Intervention Type: PROCEDURE; Name: Alveolar recruitment maneuver; Assigned to Arm(s): Individualized vent. + postop. CPAP, Individualized ventilation | Intervention Type: PROCEDURE; Name: Calculation of optimal PEEP; Assigned to Arm(s): Individualized vent. + postop. CPAP, Individualized ventilation | Intervention Type: PROCEDURE; Name: Postoperative CPAP; Assigned to Arm(s): Individualized vent. + postop. CPAP, Standard vent. + postoperative CPAP
D: Arm Label: conventional ventilation, protective ventilation; Type: OTHER; Interventions: Procedure: change ventilation | Intervention Type: PROCEDURE; Name: change ventilation; Assigned to Arm(s): conventional ventilation, protective ventilation

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2b, Dose-ranging Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults With Systemic Lupus Erythematosus
Brief Summary: To evaluate the efficacy and safety of sifalimumab compared to placebo in subjects with moderately to severely active Systemic Lupus Erythematosus (SLE).


Options:
A: Arm Label: Part A, 1 mg/kg CNTO 136; Type: EXPERIMENTAL; Interventions: Drug: 1 mg/kg CNTO 136 | Arm Label: Part A, 4 mg/kg CNTO 136; Type: EXPERIMENTAL; Interventions: Drug: 4 mg/kg CNTO 136 | Arm Label: Part A, 10 mg/kg CNTO 136; Type: EXPERIMENTAL; Interventions: Drug: 10 mg/kg CNTO 136 | Arm Label: Part B, 10 mg/kg CNTO 136/placebo; Type: EXPERIMENTAL; Interventions: Drug: 10 mg/kg CNTO 136, Drug: Placebo | Intervention Type: DRUG; Name: 1 mg/kg CNTO 136; Assigned to Arm(s): Part A, 1 mg/kg CNTO 136 | Intervention Type: DRUG; Name: 4 mg/kg CNTO 136; Assigned to Arm(s): Part A, 4 mg/kg CNTO 136 | Intervention Type: DRUG; Name: 10 mg/kg CNTO 136; Assigned to Arm(s): Part A, 10 mg/kg CNTO 136, Part B, 10 mg/kg CNTO 136/placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Part B, 10 mg/kg CNTO 136/placebo
B: Arm Label: Sifalimumab 200 milligram (mg); Type: EXPERIMENTAL; Interventions: Biological: Sifalimumab 200 mg | Arm Label: Sifalimumab 600 mg; Type: EXPERIMENTAL; Interventions: Biological: Sifalimumab 600 mg | Arm Label: Sifalimumab 1,200 mg; Type: EXPERIMENTAL; Interventions: Biological: Sifalimumab 1,200 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: BIOLOGICAL; Name: Sifalimumab 200 mg; Assigned to Arm(s): Sifalimumab 200 milligram (mg) | Intervention Type: BIOLOGICAL; Name: Sifalimumab 600 mg; Assigned to Arm(s): Sifalimumab 600 mg | Intervention Type: BIOLOGICAL; Name: Sifalimumab 1,200 mg; Assigned to Arm(s): Sifalimumab 1,200 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Lenalidomide; Type: EXPERIMENTAL; Interventions: Drug: Lenalidomide | Arm Label: Lenalidomide 2; Type: EXPERIMENTAL; Interventions: Drug: Lenalidomide | Intervention Type: DRUG; Name: Lenalidomide; Assigned to Arm(s): Lenalidomide, Lenalidomide 2
D: Arm Label: A-623 high dose weekly; Type: EXPERIMENTAL; Interventions: Drug: A-623 | Arm Label: A-623 low dose weekly; Type: EXPERIMENTAL; Interventions: Drug: A-623 | Arm Label: A-623 high dose every 4 weeks; Type: EXPERIMENTAL; Interventions: Drug: A-623 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo Comparator | Intervention Type: DRUG; Name: A-623; Assigned to Arm(s): A-623 high dose weekly | Intervention Type: DRUG; Name: A-623; Assigned to Arm(s): A-623 low dose weekly | Intervention Type: DRUG; Name: A-623; Assigned to Arm(s): A-623 high dose every 4 weeks | Intervention Type: OTHER; Name: Placebo Comparator; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Controlled Trial Evaluating the Efficacy of Polyethylene Glycol 3350-electrolyte Solution (GoLYTELY®) in Patients With Hepatic Encephalopathy.
Brief Summary: This study is being done to find out if the laxative polyethylene glycol (also known as GoLYTELY® or Miralax®) can treat your hepatic encephalopathy (confusion due to your liver disease and/or cirrhosis) better and/or more safely than lactulose (another laxative). In this study, the investigators will evaluate if polyethylene glycol (GoLYTELY®) is more effective than lactulose on neurocognition (memory and thinking skills) and determine if it decreases the hospital stay.


Options:
A: Intervention Type: DRUG; Name: HPN-100; Assigned to Arm(s): N/A
B: Arm Label: Polyethylene glycol 3350-electrolyte solution (GoLYTELY®); Type: ACTIVE_COMPARATOR; Interventions: Drug: Polyethylene glycol 3350-electrolyte solution (GoLYTELY®) | Arm Label: Lactulose; Type: OTHER; Interventions: Drug: Lactulose | Intervention Type: DRUG; Name: Polyethylene glycol 3350-electrolyte solution (GoLYTELY®); Assigned to Arm(s): Polyethylene glycol 3350-electrolyte solution (GoLYTELY®) | Intervention Type: DRUG; Name: Lactulose; Assigned to Arm(s): Lactulose
C: Arm Label: GT4P-F; Type: EXPERIMENTAL; Interventions: Drug: HPN-100 | Arm Label: GT4P-API; Type: EXPERIMENTAL; Interventions: Drug: HPN-100 | Arm Label: Ammonul; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ammonul | Arm Label: Buphenyl; Type: ACTIVE_COMPARATOR; Interventions: Drug: Buphenyl | Intervention Type: DRUG; Name: HPN-100; Assigned to Arm(s): GT4P-API, GT4P-F | Intervention Type: DRUG; Name: Ammonul; Assigned to Arm(s): Ammonul | Intervention Type: DRUG; Name: Buphenyl; Assigned to Arm(s): Buphenyl
D: Arm Label: HPN-100; Type: EXPERIMENTAL; Interventions: Drug: HPN-100 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: HPN-100; Assigned to Arm(s): HPN-100 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B